Follicular Lymphoma
From the Journals
Obinutuzumab edges out rituximab for PFS in follicular lymphoma
Three-year progression-free survival was 80% with obinutuzumab, vs. 73.3% with rituximab.
From the Journals
VCR regimen showed efficacy in mantle cell and indolent lymphomas
In the 24-patient study, the 2-year progression-free survival rate was 82% and 54% respectively for MCL and iNHL patients, respectively.
News
Newer blood cancer drugs may not improve OS, QOL
A study of cancer drugs approved by the European Commission from 2009 to 2013 showed that few hematology drugs were known to provide a benefit in...
News
EC expands approval of obinutuzumab in FL
The European Commission (EC) has expanded the marketing authorization for obinutuzumab (Gazyvaro). The drug is now approved for use in combination...
News
FDA grants accelerated approval to copanlisib for relapsed follicular lymphoma
The Food and Drug Administration has granted accelerated approval to copanlisib (Aliqopa) for the treatment of adults with relapsed follicular...
News
Trials of atezolizumab placed on partial hold
Roche has announced a partial clinical hold on 2 trials of the anti-PD-L1 antibody atezolizumab (Tecentriq). One is a phase 1b/2 study (...
News
FDA approves drug to treat relapsed FL
The US Food and Drug Administration (FDA) has granted accelerated approval to copanlisib (Aliqopa), an intravenous PI3K inhibitor developed by...
News
Immune status linked to outcomes of CAR T-cell therapy
MAINZ/FRANKFURT, GERMANY—Outcomes of treatment with a third-generation chimeric antigen receptor (CAR) T-cell therapy are associated with a...
Conference Coverage
Biosimilar matches rituximab in large follicular lymphoma trial
MADRID – The biosimilar GP2013 met the criteria for therapeutic equivalence to rituximab in a large comparator trial of previously untreated...
Conference Coverage
Biosimilar deemed equivalent to reference drug in FL
MADRID—The biosimilar GP2013 has demonstrated equivalence to its reference drug rituximab in patients with previously untreated, advanced-stage...
News
FDA grants Priority Review to Gazyva for follicular lymphoma
Gazyva (obinutuzumab) has been granted a Priority Review by the Food and Drug Administration for the treatment of previously untreated follicular...